FDA cracking down on compound GLP-1s?

Hong Kong Yanpep International
Saw a news report covering a company agreeing to stop distributing certain compounded GLP-1 medications domestically following regulatory pressure.
 
Came across coverage of a company reaching an agreement to halt sales of certain compounded GLP-1 medications in the US after regulatory scrutiny.
 
The FDA actually put out an official statement raising concerns about unapproved GLP-1 drugs being marketed for weight loss.
 
They caught onto the labeling workaround. Who'd have guessed? Twist is, apparently if sellers were also offering bac water alongside it, the FDA treats that as evidence it's meant for human use. That's a new angle. With the big online retailers pulling bac water too, it's starting to look like a coordinated pattern.
 
Since the government clampdown some months back, most US online listings call semaglutide 'GLP-1' or so, tirzepatide 'GLP-2', and retatrutide stays retatrutide (there's no 'GLP-3'). It isn't about the actual GLP-2 peptide.
 
A crackdown on peptides is on its way. Pharma wants GLPs gone, and compounders received the other peps as compensation for losing GLPs, so they'll want the rest gone too. Media cover the China peptide business daily in full public view, so the government will want to look responsive. Everything points to a clampdown. Will it disappear? Of course not. Harder to find and slower to get? Yep. Pricier as seizures rise and margins shrink? Also yep. Best time to build a stash was yesterday, second best is today.
 
You must log in or register to reply here.
Back
Top